Phospholipid organization in monkey erythrocytes upon Plasmodium knowlesi infection.
The phospholipid organization in monkey erythrocytes upon Plasmodium knowlesi infection has been studied. Parasitized and nonparasitized erythrocytes from malaria-infected blood were separated and pure erythrocyte membranes from parasitized cells were isolated using Affi-Gel beads. In this way, the phospholipid content and composition of the membrane of nonparasitized cells, the erythrocyte membrane of parasitized cells and the parasite could be determined. The phospholipid content and composition of the erythrocyte membranes of nonparasitized and parasitized cells and erythrocytes from chloroquine-treated monkeys cured from malaria, were the same as in normal erythrocytes. The phospholipid content of the parasite increased during its development, but its composition remained unchanged. Three independent techniques, i.e., treatment of intact cells with phospholipase A2 and sphingomyelinase C, fluorescamine labeling of aminophospholipids and a phosphatidylcholine-transfer protein-mediated exchange procedure have been applied to assess the disposition of phospholipids in: erythrocytes from healthy monkeys, nonparasitized and parasitized erythrocytes from monkeys infected with Plasmodium knowlesi, and erythrocytes from monkeys that had been cured from malaria by chloroquine treatment. The results obtained by these experiments do not show any abnormality in phospholipid asymmetry in the erythrocyte from malaria-infected (splenectomized) monkeys, neither in the nonparasitized cells, nor in the parasitized cells at any stage of parasite development. Nevertheless, a considerable degree of lipid bilayer destabilization in the membrane of the parasitized cells is apparent from the enhanced exchangeability of the PC from those cells, as well as from their increased permeability towards fluorescamine.
D000727:Androgen-Binding Protein; D000818:Animals; D002352:Carrier Proteins / Q000378:metabolism; D002463:Cell Membrane Permeability; D002738:Chloroquine / Q000627:therapeutic use; D004910:Erythrocyte Membrane / Q000378:metabolism* / Q000469:parasitology; D004912:Erythrocytes / Q000469:parasitology; D005450:Fluorescamine / Q000378:metabolism; D008051:Lipid Bilayers / Q000378:metabolism; D008253:Macaca mulatta; D008288:Malaria / Q000097:blood* / Q000188:drug therapy; D010741:Phospholipases A / Q000378:metabolism; D054467:Phospholipases A2; D049294:Phospholipid Transfer Proteins; D010743:Phospholipids / Q000097:blood* / Q000378:metabolism; D010961:Plasmodium / Q000378:metabolism; D013108:Sphingomyelin Phosphodiesterase / Q000378:metabolism
D000727:Androgen-Binding Protein; D002352:Carrier Proteins; D008051:Lipid Bilayers; D049294:Phospholipid Transfer Proteins; D010743:Phospholipids; D005450:Fluorescamine; D002738:Chloroquine; D010741:Phospholipases A; D054467:Phospholipases A2; D013108:Sphingomyelin Phosphodiesterase